PR83522

MENLO PARK, California, April 1, 2020 /PRNewswire=KYODO JBN/ --

IONpath, Inc. today announces that they have jointly authored with Bristol

Myers Squibb an article entitled Multiplexed Ion Beam Imaging (MIBI) for

Characterization of the Tumor Microenvironment Across Tumor Types ( https://www.nature.com/articles/s41374-020-0417-4.epdf?author_access_token=cwXGgzBsmiumdO6quHkYlNRgN0jAjWel9jnR3ZoTv0NlnopzdPSm7XpvXf8bJs2AadJmwkcf2THYmtjkZ_Td8rjA4Ypztz-0EprZWeM5BiG7lB1oDX1S3vt8kiBwWzhtqA1JV17fbHuHLYCWmdKQiQ%3D%3D ) for the Nature journal Laboratory Investigation.

Info - https://mma.prnewswire.com/media/1139769/Figure_5_final_Infographic.jpg

Info - https://mma.prnewswire.com/media/1139770/Figure_6_final_Infographic.jpg

Logo - https://mma.prnewswire.com/media/1088947/IONpath_Logo.jpg

The ability to understand all the cells present within a tumor by

differentiating several cell types at once in a single tissue section has been

limited by the technology available. Here the authors showed how Multiplexed

Ion Beam Imaging (MIBI(TM)) is able to detail the features of a wide variety of

tumor types by providing cell phenotype identification coupled with analysis of

their spatial relationships. For this collaboration, Bristol Myers Squibb

provided samples from 50 tumor biopsies to IONpath where they were

simultaneously stained with a panel of 15 antibodies, each labeled with a

specific metal isotope. Highly detailed mapping of the tumor microenvironment

provided an immune profile(fig 1) and spatial organization(fig 2) through a

multi-step process that segmented the sample down to the individual cell.

This information was gathered as an exercise to observe the characteristics of

the samples in question. However, the implications of this new level of tumor

mapping at a cellular level could be far reaching. Scientists and drug

developers are now able to measure the proximity of immune cells to cancer

cells and, within the same sample, measure the protein expression levels of

potential drug targets and other variables associated with response to certain

therapies such as those targeting immune checkpoints.

"It is IONpath's mission to empower medical discovery, specifically in the area

of immuno-oncology, through the characterization of the tumor microenvironment

down to the cellular level," said Dr. Jessica Finn, Director of Pathology and

one of the authors of the article. Dr. Finn adds, "Examining these detailed

and interrelated structures is difficult but important work in the fight to

cure certain types of cancer."

As an example of how this mission for IONpath may impact real world decisions,

this study demonstrated the possibilities for calculating distances between

different cell subsets including tumor and immune cells in addition to PD-1 and

PD-L1 expressing immune cell subsets. Further studies in this area may be

designed to support better outcomes in the field of immuno-oncology.

Experience how IONpath enables clients and collaborators to examine data via

its web enabled visualization platform MIBItracker(TM). Log into

MIBItracker(TM) through this link (

https://c212.net/c/link/?t=0&l=en&o=2765288-1&h=2814282971&u=http%3A%2F%2Fmibi-share.ionpath.com%2F&a=through+this+link.

) .

About IONpath, Inc. and IONpath Research Services

IONpath, Inc. is revolutionizing tissue imaging to accelerate medical discovery

and improve human health. The company's MIBIscope(TM) System utilizes

Multiplexed Ion Beam Imaging (MIBI(TM)) technology, developed at Stanford

University, and represents a transformative step in tissue imaging by

simultaneously multiplexing up to 40 markers with specificity down to a single

cell. Leading research institutes, biotech and pharmaceutical companies are

using the MIBIscope in immuno-oncology, immunology and neuroscience research

where high-fidelity multiplexed imaging data is needed. In addition to the

MIBIscope(TM) System enhanced with MIBItracker(TM), IONpath empowers the

research and development initiatives of academic, biotech and pharmaceutical

partners through its comprehensive Research Services division.

Visit www.ionpath.com to learn more.

(C)2020 IONpath, Inc. All rights reserved. IONpath(R) is a registered trademark

and MIBI(TM) & MIBIscope(TM) are trademarks of IONpath INC. For Research Use

Only. Not for diagnostic use.

IONpath Media Relations Phone: +1 305-803-0824

Terri Hnatyszyn Email: media@ionpath.com

Marketing & Communications

SOURCE IONpath, Inc.